Can-Fite Advances Namodenoson into Phase 2b Pancreatic Cancer Trial with Immunotherapy
Event summary
- Can-Fite to initiate Phase 2b study combining Namodenoson with immunotherapy for advanced pancreatic cancer.
- Phase 2a data showed stable disease in >30% of patients, with 35% remaining on therapy.
- Study design details to be discussed at BIO International Convention in San Diego.
- Company in partnership negotiations with leading oncology companies.
The big picture
Can-Fite's advancement of Namodenoson into a Phase 2b combination study reflects growing interest in targeted therapies for pancreatic cancer, an area with significant unmet medical need. The move comes as immunotherapy combinations gain traction in oncology, potentially expanding treatment options for one of the deadliest cancers. Success in this trial could position Namodenoson as a key player in the pancreatic cancer landscape, while strategic partnerships may accelerate its commercial potential.
What we're watching
- Clinical Efficacy
- Whether Namodenoson's combination with immunotherapy will demonstrate meaningful improvements in progression-free and overall survival.
- Partnership Dynamics
- The pace at which Can-Fite secures strategic partnerships for its pancreatic cancer program.
- Regulatory Pathway
- How the Orphan Drug Designation will influence Namodenoson's development timeline and commercialization strategy.
Related topics